ANAB
AnaptysBio, Inc.
Biotechnology
Market Cap$2.89B
5Y Perf.+320.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ANAB vs ARQT vs DAWN vs REGN
Revenue, margins, valuation, and 5-year total return — side by side.
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-21.6%
DAWN
Day One Biopharmaceuticals, Inc.
Biotechnology
Market Cap$2.22B
5Y Perf.-9.5%
REGN
Regeneron Pharmaceuticals, Inc.
Biotechnology
Market Cap$73.68B
5Y Perf.+41.1%
ANAB vs ARQT vs DAWN vs REGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ANAB | ARQT | DAWN | REGN |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $2.89B | $2.58B | $2.22B | $73.68B |
| Revenue (TTM) | $235M | $416M | $158M | $14.92B |
| Net Income (TTM) | $-13M | $-2M | $-107M | $4.42B |
| Gross Margin | 99.0% | 90.9% | 89.1% | 84.5% |
| Operating Margin | 20.4% | 0.8% | -80.8% | 24.3% |
| Forward P/E | — | 77.6x | — | 15.3x |
| Total Debt | $14M | $6M | $3M | $2.71B |
| Cash & Equiv. | $238M | $43M | $197M | $3.12B |
ANAB vs ARQT vs DAWN vs REGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANAB
ARQT
DAWN
REGN
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| AnaptysBio, Inc. (ANAB) | 100 | 420.9 | +320.9% |
| Arcutis Biotherapeu… (ARQT) | 100 | 78.4 | -21.6% |
| Day One Biopharmace… (DAWN) | 100 | 90.5 | -9.5% |
| Regeneron Pharmaceu… (REGN) | 100 | 141.1 | +41.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANAB vs ARQT vs DAWN vs REGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REGN leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AnaptysBio, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. DAWN also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ANAB
AnaptysBio, Inc.
The Growth Play
ANAB is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 157.0%, EPS growth 91.0%, 3Y rev CAGR 183.6%
- 491.0% 10Y total return vs REGN's 90.0%
- 157.0% revenue growth vs REGN's 1.0%
- +410.4% vs REGN's +27.1%
Best for: growth exposure and long-term compounding
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Angle
ARQT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
DAWN
Day One Biopharmaceuticals, Inc.
The Income Pick
DAWN is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.35
- Lower volatility, beta 0.35, Low D/E 0.6%, current ratio 8.02x
- Beta 0.35, current ratio 8.02x
- Beta 0.35 vs ARQT's 1.48, lower leverage
Best for: income & stability and sleep-well-at-night
REGN
Regeneron Pharmaceuticals, Inc.
The Value Play
REGN carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 29.6% margin vs DAWN's -67.8%
- 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend
- 11.1% ROA vs DAWN's -20.7%, ROIC 8.9% vs -30.5%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ANAB | 157.0% revenue growth vs REGN's 1.0% |
| Value | REGN | Better valuation composite |
| Quality / Margins | REGN | 29.6% margin vs DAWN's -67.8% |
| Stability / Safety | DAWN | Beta 0.35 vs ARQT's 1.48, lower leverage |
| Dividends | REGN | 0.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | ANAB | +410.4% vs REGN's +27.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs DAWN's -20.7%, ROIC 8.9% vs -30.5% |
ANAB vs ARQT vs DAWN vs REGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2023
FY 2025
FY 2025
ANAB vs ARQT vs DAWN vs REGN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLREGNLAGGINGARQT
Who Leads Where
REGN leads in 2 of 6 categories
ANAB leads 1 • DAWN leads 1 • ARQT leads 0 • 1 tied
Explore the data ↓ARQTArcutis Biotherapeuti…
0leads
DAWNDay One Biopharmaceut…
1leads
ANABAnaptysBio, Inc.
1leads
REGNRegeneron Pharmaceuti…
2leads
6 Total Categories
CATEGORYLEADERvs ANABvs DAWNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
REGN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REGN4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ANAB5/6
Risk & VolatilityBeta, volatility, and downside exposure
DAWN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — ANAB and REGN each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
REGN is the larger business by revenue, generating $14.9B annually — 94.3x DAWN's $158M. REGN is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to DAWN's -67.8%. On growth, ANAB holds the edge at +151.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $235M | $416M | $158M | $14.9B |
| EBITDAEarnings before interest/tax | $50M | $6M | -$124M | $4.2B |
| Net IncomeAfter-tax profit | -$13M | -$2M | -$107M | $4.4B |
| Free Cash FlowCash after capex | $20M | $27M | -$108M | $4.2B |
| Gross MarginGross profit ÷ Revenue | +99.0% | +90.9% | +89.1% | +84.5% |
| Operating MarginEBIT ÷ Revenue | +20.4% | +0.8% | -80.8% | +24.3% |
| Net MarginNet income ÷ Revenue | -5.6% | -0.6% | -67.8% | +29.6% |
| FCF MarginFCF ÷ Revenue | +8.4% | +6.5% | -68.0% | +27.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +151.1% | +60.1% | +83.9% | +19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.1% | +55.0% | +70.0% | -7.2% |
Evenly matched — ANAB and REGN each lead in 3 of 6 comparable metrics.
Valuation Metrics
REGN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, REGN's 17.8x EV/EBITDA is more attractive than ANAB's 52.9x.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Market CapShares × price | $2.9B | $2.6B | $2.2B | $73.7B |
| Enterprise ValueMkt cap + debt − cash | $2.7B | $2.5B | $2.0B | $73.3B |
| Trailing P/EPrice ÷ TTM EPS | -145.57x | -158.92x | -20.70x | 17.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 77.64x | — | 15.35x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 2.70x |
| EV / EBITDAEnterprise value multiple | 52.93x | — | — | 17.78x |
| Price / SalesMarket cap ÷ Revenue | 12.31x | 6.87x | 14.06x | 5.14x |
| Price / BookPrice ÷ Book value/share | 56.40x | 13.87x | 5.05x | 2.46x |
| Price / FCFMarket cap ÷ FCF | 147.25x | — | — | 18.06x |
REGN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
REGN leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
REGN delivers a 14.3% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-24 for ANAB. DAWN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ANAB's 0.38x. On the Piotroski fundamental quality scale (0–9), ANAB scores 6/9 vs DAWN's 4/9, reflecting solid financial health.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -24.5% | -1.4% | -23.4% | +14.3% |
| ROA (TTM)Return on assets | -3.6% | -0.6% | -20.7% | +11.1% |
| ROICReturn on invested capital | +55.1% | -5.2% | -30.5% | +8.9% |
| ROCEReturn on capital employed | +12.5% | -4.3% | -26.7% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.38x | 0.03x | 0.01x | 0.09x |
| Net DebtTotal debt minus cash | -$224M | -$37M | -$194M | -$412M |
| Cash & Equiv.Liquid assets | $238M | $43M | $197M | $3.1B |
| Total DebtShort + long-term debt | $14M | $6M | $3M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 0.81x | 2.08x | — | 108.44x |
REGN leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ANAB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANAB five years ago would be worth $38,394 today (with dividends reinvested), compared to $6,053 for ARQT. Over the past 12 months, ANAB leads with a +410.4% total return vs REGN's +27.1%. The 3-year compound annual growth rate (CAGR) favors ANAB at 68.0% vs REGN's -1.7% — a key indicator of consistent wealth creation.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +123.4% | -28.8% | +143.3% | -8.5% |
| 1-Year ReturnPast 12 months | +410.4% | +50.8% | +241.7% | +27.1% |
| 3-Year ReturnCumulative with dividends | +374.6% | +44.9% | +65.1% | -5.1% |
| 5-Year ReturnCumulative with dividends | +283.9% | -39.5% | -8.4% | +43.6% |
| 10-Year ReturnCumulative with dividends | +491.0% | -5.2% | -8.4% | +90.0% |
| CAGR (3Y)Annualised 3-year return | +68.0% | +13.2% | +18.2% | -1.7% |
ANAB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
DAWN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DAWN is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than ARQT's 1.48 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DAWN currently trades 100.0% from its 52-week high vs ARQT's 65.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.00x | 1.48x | 0.35x | 0.81x |
| 52-Week HighHighest price in past year | $72.36 | $31.77 | $21.53 | $821.11 |
| 52-Week LowLowest price in past year | $11.41 | $12.42 | $5.64 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +92.5% | +65.0% | +100.0% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 70.9 | 54.3 | 80.3 | 44.9 |
| Avg Volume (50D)Average daily shares traded | 895K | 1.3M | 4.9M | 631K |
DAWN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ANAB as "Buy", ARQT as "Buy", DAWN as "Buy", REGN as "Buy". Consensus price targets imply 71.8% upside for ARQT (target: $36) vs 10.3% for DAWN (target: $24). REGN is the only dividend payer here at 0.48% yield — a key consideration for income-focused portfolios.
| Metric | ANABAnaptysBio, Inc. | ARQTArcutis Biotherap… | DAWNDay One Biopharma… | REGNRegeneron Pharmac… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $73.88 | $35.50 | $23.75 | $865.68 |
| # AnalystsCovering analysts | 22 | 12 | 12 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +0.5% |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +2.4% | 0.0% | 0.0% | +5.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
REGN leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). ANAB leads in 1 (Total Returns). 1 tied.
Best OverallRegeneron Pharmaceuticals, … (REGN)Leads 2 of 6 categories
Loading custom metrics...
ANAB vs ARQT vs DAWN vs REGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ANAB or ARQT or DAWN or REGN a better buy right now?
For growth investors, AnaptysBio, Inc.
(ANAB) is the stronger pick with 157. 0% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate AnaptysBio, Inc. (ANAB) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ANAB or ARQT or DAWN or REGN?
On forward P/E, Regeneron Pharmaceuticals, Inc.
is actually cheaper at 15. 3x.
03Which is the better long-term investment — ANAB or ARQT or DAWN or REGN?
Over the past 5 years, AnaptysBio, Inc.
(ANAB) delivered a total return of +283. 9%, compared to -39. 5% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: ANAB returned +491. 0% versus DAWN's -8. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ANAB or ARQT or DAWN or REGN?
By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.
(DAWN) is the lower-risk stock at 0. 35β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 318% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Day One Biopharmaceuticals, Inc. (DAWN) carries a lower debt/equity ratio of 1% versus 38% for AnaptysBio, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ANAB or ARQT or DAWN or REGN?
By revenue growth (latest reported year), AnaptysBio, Inc.
(ANAB) is pulling ahead at 157. 0% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: AnaptysBio, Inc. grew EPS 91. 0% year-over-year, compared to -2. 0% for Day One Biopharmaceuticals, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ANAB or ARQT or DAWN or REGN?
Regeneron Pharmaceuticals, Inc.
(REGN) is the more profitable company, earning 31. 4% net margin versus -67. 8% for Day One Biopharmaceuticals, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -80. 8% for DAWN. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ANAB or ARQT or DAWN or REGN more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc.
(REGN) trades at 15. 3x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 62. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 71. 8% to $35. 50.
08Which pays a better dividend — ANAB or ARQT or DAWN or REGN?
In this comparison, REGN (0.
5% yield) pays a dividend. ANAB, ARQT, DAWN do not pay a meaningful dividend and should not be held primarily for income.
09Is ANAB or ARQT or DAWN or REGN better for a retirement portfolio?
For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.
(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35)). Both have compounded well over 10 years (DAWN: -8. 4%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ANAB and ARQT and DAWN and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ANAB is a small-cap high-growth stock; ARQT is a small-cap high-growth stock; DAWN is a small-cap high-growth stock; REGN is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ANAB: 151.1% · ARQT: 60.1%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.